Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers

Aim: To verify the relationship between ARID1A and tumor immune microenvironment thus immune checkpoint inhibitors (ICIs) response. Material & methods: Several public databases were used to characterize the association between ARID1A gene alteration and tumor immunity. Results: The gene mutation...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2020-10, Vol.16 (29), p.2295-2306
Main Authors: Li, Zhenxiang, Lin, Jiamao, Zhang, Lijuan, Li, Jingchao, Zhang, Yingyun, Zhao, Chenglong, Wang, Haiyong
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Cell cycle
Deoxyribonucleic acid
DNA
Gene expression
Genomics
Medical prognosis
Mutation
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To verify the relationship between ARID1A and tumor immune microenvironment thus immune checkpoint inhibitors (ICIs) response. Material & methods: Several public databases were used to characterize the association between ARID1A gene alteration and tumor immunity. Results: The gene mutation frequency was 8.2% in all cancer types. The ARID1A-mutated cancers have higher scores of mutation count, tumor mutational burden, neoantigen load (p < 0.001) and T cell repertoire, B cell repertoire diversity (p < 0.05). The gene mutation has tight association with multiple-activated immune cells. Survival analysis suggested that patients with ARID1A mutant cancers benefit more from ICIs treatment (p = 0.013). Conclusion: The ARID1A gene mutation was correlated with higher tumor immunogenicity and activated antitumor immune microenvironment, resulting in superior cohort that respond well to ICIs.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-0243